Vol 62, No 5 (2005)
Other
Published online: 2005-12-12
Submitted: 2012-12-28
Get Citation

Efficacy and safety of oral l-arginine in acute myocardial infarction. Results of multicenter, randomized, double-blind, placebo-controlled ARAMI pilot trial

Bronisław Bednarz, Tomasz Jaxa-Chamiec, Paweł Maciejewski, Michał Szpajer, Krzysztof Janik, Jacek Gniot, Teresa Kawka-Urbanek, Dorota Drozdowska, Jacek Gessek, Henryk Laskowski
Kardiol Pol 2005;62(5):427-427.
Vol 62, No 5 (2005)
Other
Published online: 2005-12-12
Submitted: 2012-12-28

Abstract

Aims: L-arginine is a substrate for nitric oxide (NO) synthesis in vascular endothelial cells. NO bioavailability is decreased during myocardial infarction (MI). It might be expected that administration of L-arginine may maintain NO production and alleviate the course of MI. The aim of the study was to assess safety and effects of treatment with L-arginine on the clinical course of MI.
Methods and Results: 792 patients (mean age 64 years, 551 men) with ST segment elevation MI admitted within 24h after the onset of symptoms were randomized to oral L-arginine (3.0 t.i.d p.o. for 30 days) or placebo on top of routine therapy. The end point which was the composite of 30 day cardiovascular death, reinfarction, successful resuscitation, shock/pulmonary edema or recurrent myocardial ischemia occurred in 24% patients treated with L-arginine and 27% with placebo (OR 0.63, 95% CI 0.39-1.02, p=0.06). The end point was observed less frequently in 226 patients with hyperlipidemia (19 vs 31, p

Abstract

Aims: L-arginine is a substrate for nitric oxide (NO) synthesis in vascular endothelial cells. NO bioavailability is decreased during myocardial infarction (MI). It might be expected that administration of L-arginine may maintain NO production and alleviate the course of MI. The aim of the study was to assess safety and effects of treatment with L-arginine on the clinical course of MI.
Methods and Results: 792 patients (mean age 64 years, 551 men) with ST segment elevation MI admitted within 24h after the onset of symptoms were randomized to oral L-arginine (3.0 t.i.d p.o. for 30 days) or placebo on top of routine therapy. The end point which was the composite of 30 day cardiovascular death, reinfarction, successful resuscitation, shock/pulmonary edema or recurrent myocardial ischemia occurred in 24% patients treated with L-arginine and 27% with placebo (OR 0.63, 95% CI 0.39-1.02, p=0.06). The end point was observed less frequently in 226 patients with hyperlipidemia (19 vs 31, p
Get Citation

Keywords

l-arginine - myocardial infarction

About this article
Title

Efficacy and safety of oral l-arginine in acute myocardial infarction. Results of multicenter, randomized, double-blind, placebo-controlled ARAMI pilot trial

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 62, No 5 (2005)

Pages

427-427

Published online

2005-12-12

Bibliographic record

Kardiol Pol 2005;62(5):427-427.

Keywords

l-arginine - myocardial infarction

Authors

Bronisław Bednarz
Tomasz Jaxa-Chamiec
Paweł Maciejewski
Michał Szpajer
Krzysztof Janik
Jacek Gniot
Teresa Kawka-Urbanek
Dorota Drozdowska
Jacek Gessek
Henryk Laskowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl